This lecture by Professor Christoph Wanner emphasizes the importance of early diagnosis and treatment of chronic kidney disease (CKD), particularly in patients with cardiovascular comorbidities, advocating for

Learn more about the benefits of early sodium-glucose cotransporter 2 inhibitor initiation for heart failure patients, both in the acute and chronic settings, in improving CV and hospitalization outcomes and mitigating the damage of upstream cardio-renal-metabolic (CRM) risk factors.